ZNF562 Inhibitors
Chemical inhibitors of ZNF562 function by modulating various signaling pathways that ultimately control the activity of this protein. Wortmannin and LY294002 are both inhibitors of phosphoinositide 3-kinases (PI3K), which are critical components of the PI3K/AKT signaling pathway. By inhibiting PI3K, these chemicals prevent the phosphorylation and subsequent activation of AKT, leading to a reduction in ZNF562 activity due to decreased signaling through this pathway. Rapamycin, targeting the mTOR pathway, also impacts ZNF562 activity since mTOR is a key regulator of cell growth and proliferation, and its inhibition results in the dampening of the signals that contribute to the functional state of ZNF562.
Further influencing the activity of ZNF562 is the inhibition of the MAPK pathway by PD 98059 and U0126, which specifically inhibit MEK. This blockade prevents the activation of ERK, another kinase downstream in the MAPK cascade, thus impairing the signaling required for optimal ZNF562 activity. SB203580 and SP600125, which target p38 MAP kinase and JNK respectively, also reduce ZNF562 activity by inhibiting other branches of the MAPK pathway. Additionally, the EGFR inhibitors Gefitinib and Erlotinib disrupt the signaling emanating from the epidermal growth factor receptor, which is an upstream regulator of several signaling cascades, including those that modulate ZNF562 activity. By interfering with EGFR, these inhibitors contribute to reducing the functional activity of ZNF562. Lastly, Sorafenib, Dasatinib, and Imatinib each target different kinases such as RAF, BCR-ABL, Src family kinases, c-Kit, and PDGFR.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a specific inhibitor of phosphoinositide 3-kinases (PI3K). By inhibiting PI3K, it prevents the phosphorylation and activation of AKT, a downstream target. Since ZNF562 has been shown to be regulated through PI3K/AKT signaling, the inhibition of this pathway by Wortmannin would lead to decreased activation of ZNF562, resulting in its functional inhibition. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is another PI3K inhibitor, similar in function to Wortmannin. It blocks the PI3K/AKT pathway, leading to reduced phosphorylation and activation of downstream proteins. Inhibition of PI3K by LY294002 would thus impede the activation of ZNF562 by this pathway, effectively inhibiting the protein's function. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin is an inhibitor of the mTOR (mammalian target of rapamycin) pathway, which is involved in cell growth and proliferation. Given that ZNF562 is potentially regulated by pathways controlled by mTOR, the inhibition of mTOR by Rapamycin would lead to a decrease in ZNF562 activity, contributing to its functional inhibition. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD 98059 is a selective inhibitor of MEK, which prevents the activation of ERK, a downstream kinase in the MAPK pathway. Since the MAPK pathway has been implicated in the regulation of ZNF562, inhibiting MEK with PD 98059 would reduce ERK activity and thus ZNF562 activity, leading to its functional inhibition. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 acts similarly to PD 98059 as a MEK inhibitor. By preventing MEK from activating ERK, it disrupts the MAPK signaling cascade. The inhibition of this pathway is known to decrease the activity of ZNF562, thereby functionally inhibiting the protein. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a specific inhibitor of p38 MAP kinase, part of the MAPK pathway. Inhibition of p38 MAP kinase results in decreased activation of downstream targets, including ZNF562, thus functionally inhibiting the protein. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of JNK, another kinase within the MAPK pathway. Inhibiting JNK activity would lead to reduced signaling towards proteins regulated by this pathway, including ZNF562, functionally inhibiting its activity. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $63.00 $114.00 $218.00 $349.00 | 74 | |
Gefitinib selectively inhibits the epidermal growth factor receptor (EGFR) tyrosine kinase, which is involved in the regulation of cellular proliferation and survival. Through the inhibition of EGFR, downstream signaling that may regulate ZNF562 is disrupted, leading to the functional inhibition of ZNF562. | ||||||
Erlotinib, Free Base | 183321-74-6 | sc-396113 sc-396113A sc-396113B sc-396113C sc-396113D | 500 mg 1 g 5 g 10 g 100 g | $87.00 $135.00 $293.00 $505.00 $3827.00 | 42 | |
Erlotinib, like Gefitinib, is an EGFR tyrosine kinase inhibitor. By blocking the EGFR signaling pathway, Erlotinib would lead to a decrease in the functional activity of downstream proteins, including ZNF562, resulting in its inhibition. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Sorafenib is a multi-kinase inhibitor that targets RAF kinases, among others. By inhibiting RAF and disrupting the RAF/MEK/ERK pathway, Sorafenib would impair the activation of ZNF562, leading to its functional inhibition. | ||||||